UK markets open in 2 hours 23 minutes

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.54-0.17 (-1.59%)
At close: 04:00PM EDT
10.54 0.00 (0.00%)
After hours: 05:34PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.71
Open10.70
Bid10.50 x 1000
Ask10.54 x 1000
Day's range10.50 - 10.78
52-week range9.70 - 14.57
Volume1,380,367
Avg. volume3,046,225
Market cap3.164B
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

    PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensu

  • GlobeNewswire

    Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

    PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen 44th Annual Health Care Conference in Boston, MA, on Monday, March 4, 2024, at 11:10 a.m. E.T.Leerink Partners 2024 Global Biopharma Conference in Miami, FL on Monday, March 11, 2024, at 3:20 p.m. E.T. A live audio webcast of each presentation can also be accessed via the investors s

  • GlobeNewswire

    Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates

    2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medi